Description
Cervavac is India's first indigenously developed quadrivalent HPV vaccine designed to protect against certain high-risk strains of human papillomavirus (HPV), which are the leading causes of cervical cancer. The vaccine targets HPV types 6, 11, 16, and 18.
Target Diseases
- Cervical Cancer: Primarily caused by HPV types 16 and 18. Genital Warts: Caused by HPV types 6 and 11. Other HPV-related cancers
- including anal
- vulvar
- and vaginal cancers.
Dosage Schedule
Ages 9–14 years: Two doses, with a 6–12 month interval between doses. Ages 15 years and older: Three doses at 0, 1–2 months, and 6 months.
Possible Side Effects
- common:%20Pain
- %20swelling
- %20or%20redness%20at%20the%20injection%20site;%20mild%20fever;%20headache;%20fatigue.%0ARare%3A%20Allergic%20reactions
- %20dizziness
- %20or%20fainting%20(more%20common%20in%20adolescents).%0A
Contraindications
- Severe allergic reaction to any previous dose of an HPV vaccine or its components. Pregnant women are generally advised to delay vaccination until after pregnancy.
Additional Information
- Cervavac offers a cost-effective solution for HPV vaccination in India
- aiming to make cervical cancer prevention more accessible. Part of government and public health campaigns to reduce cervical cancer mortality in India and globally.
Storage Requirements
- Store at 2°C–8°C (36°F–46°F). Do not freeze. Protect from light.
